• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Destruxin B

Destruxin B

Product ID D183745
Cas No. 2503-26-6
Purity ≥96%
Product Unit SizeCostQuantityStock
100 µg $102.30 In stock
1 mg $613.20 In stock
5 mg $2,452.90 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Destruxin B, a cyclic depsipeptide, is a secondary metabolite isolated from the fungus Metarhizium anisopliae. Each of the mycotoxins, destruxin A, B, and E, were individually found to display antitumor effects on leukemic cells in vitro. In addition, each destruxin was found to produce antiproliferative effects in colon cancer cells and to inhibit the migration and tube formation of human endothelial cells. Although the inhibition of vacuolar-type ATPase by destruxin B has been found to be weaker than bafilomycin A1, inhibition by destruxin B was found to be readily reversible, which makes it more useful as a probe of V-ATPase function. In human colorectal cancer cells destruxin B treatment resulted in suppressed proliferation and induced cell cycle arrest. Administration of destruxin B to human non-Hodgkin lumphoma cells resulted in apoptosis induced by attenuation of the mitochondrial membrane potential.

Product Info

Cas No.

2503-26-6

Purity

≥96%

Formula

C30H51N5O7

Formula Wt.

593.77

Chemical Name

Destruxin B

IUPAC Name

16-butan-2-yl-10,11,14-trimethyl-3-(2-methylpropyl)-13-propan-2-yl-4-oxa-1,8,11,14,17-pentazabicyclo[17.3.0]docosane-2,5,9,12,15,18-hexone

Synonym

MLS002702090; AC1L8LE6; MEGxm0_000393

Melting Point

230-240°C

Appearance

White powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

D183745 MSDS PDF

Info Sheet

D183745 Info Sheet PDF

References

Yeh CT, Rao YK, Ye M, et al. Preclinical evaluation of destruxin B as a novel Wnt signaling target suppressing proliferation and metastasis of colorectal cancer using non-invasive bioluminescence imaging. Toxicol Appl Pharmacol. 2012 May 15;261(1):31-41. PMID: 22465936.

Odier F, Vey A, Bureau JP. In vitro effect of fungal cyclodepsipeptides on leukemic cells: study of destruxins A, B, and E. Biol Cell. 1992;74(3):267-271. PMID: 1628110.

Dornetshuber-Fleiss R, Heffeter P, Mohr T, et al. Destruxins: fungal-derived cyclohexadepsipeptides with multifaceted anticancer and antiangiogenic activities. Biochem Pharmacol. 2013 Aug 1;86(3):361-377. PMID: 23747344.

Muroi M, Shiragami N, Takatsuki A. Destruxin B, a specific and readily reversible inhibitor of vacuolar-type H(+)-translocating ATPase. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1358-1365. PMID: 7802670.

Chao PZ, Chin YP, Hsu IU, et al. Apoptotic toxicity of destruxin B in human non-Hodgkin lymphoma cells. Toxicol In Vitro. 2013 Sep;27(6):1870-1876. PMID: 23751424.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • B3472

    4,4′-(1,1′-Biphenyl-4,4′-diyldioxy)dianiline

    Potential VEGFR2, Met, RET, Axl, Ron, PDGFR, FG...

    ≥98%
  • C3262

    Ciprofloxacin

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥98%
  • N3323

    Nifuratel

    Nitrofuran derivative.

    ≥99%
  • P6264

    PPQ-102

    Pyramido-pyrrolo-quinoxalinedione; CFTR blocker...

    ≥98%
  • T564092

    γ-Tocopherol

    Vitamin E component

    ≥98%
  • C0016

    Caerulomycin A

    Bipyridamine toxin.

    ≥96%
  • A980005

    AZ-5104

    Inhibitor of EGFR.

    ≥98%
  • F1992

    Fexaramine

    FXR agonist.

    ≥98%
  • D3210

    Diclofenac free acid

    Somewhat selective in inhibiting COX-2 over COX...

    ≥99%
  • M2076

    Metformin Hydrochloride

    AMPK activator.

    ≥98%
  • A4445

    Allopurinol

    Purine (hypoxanthine) analog; xanthine oxidase ...

    ≥98%
  • R0351

    Ramoplanin

    Peptide; peptidoglycan inhibitor.

    ≥90%
  • G1849

    Gemifloxacin Mesylate

    Fluoroquinolone; bacterial DNA gyrase inhibitor...

    ≥98%
  • R1627

    Regorafenib Anhydrous

    Multikinase inhibitor.

    ≥99%
  • M7200

    MS436

    BRD4 inhibitor.

    ≥99%
  • E6997

    Erythropoietin, Human Recombinant

    Endogenous glycoprotein hormone involved in red...

    ≥97%
  • C5592

    CNX-774

    BTK inhibitor.

    ≥98%
  • S0170

    Sarafloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV and bacterial...

    ≥95%
  • I4961

    Imperatorin

    Furocoumarin; voltage-gated Na+ channel blocker...

    ≥98%
  • D3352

    Dinaciclib

    BRD binding agent, CDK1/2/5/9 inhibitor.

    ≥99%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only